Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes.

Pharmacokinetic/pharmacodynamic (PK/PD) modeling of antitumor agents has been developed for doxorubicin (DOX) in order to predict the optimum conditions for a drug carrier to maximize the antitumor effect. A PK model was constructed for free and liposomal doxorubicin using a hybrid model wherein the disposition in the whole body is described by compartment models, which were linked to the tumor compartment via the blood flow rate. The PD model for doxorubicin was described by a cell-kill kinetic model, which represents the number of tumor cells quantitatively, as a function of the free concentration of doxorubicin in the tumor compartment. The influence of each parameter on the antitumor effects was examined by sensitivity analysis based on the PK/PD model, which clearly showed the importance of optimizing the release rate of DOX from liposomes. The validity of the model has been tested using animal experiments. Preliminary simulations were also performed for humans after scaling up the PK/PD model from rodents to humans. The optimum conditions in the rate of drug release from liposomes were different for rodents vis-a-vis humans, which indicates the limitations involved in extrapolating optimum conditions for experimental animals to those for humans.

[1]  M. Bally,et al.  Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. , 1990, Biochimica et biophysica acta.

[2]  John W. Park,et al.  Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  H. Eichholtz-Wirth,et al.  Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro. , 1980, British Journal of Cancer.

[4]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[6]  Y. Sugiyama,et al.  Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. , 1989, Cancer research.

[7]  S. Piscitelli,et al.  Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer , 1993, Clinical pharmacology and therapeutics.

[8]  K. D. Hartman,et al.  Lymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to rats. , 1981, Cancer research.

[9]  N. Shapiro,et al.  Tumor growth and chemotherapy: Mathematical methods, computer simulations, and experimental foundations , 1973 .

[10]  M. Inaba.  Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant subline of P388 leukemia. , 1978 .

[11]  S. Stewart,et al.  Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W J Jusko,et al.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.

[13]  J. Schultz,et al.  Exchange of macromolecules between peritoneal cavity and plasma. , 1985, The American journal of physiology.

[14]  D. Friend,et al.  Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. , 1992, Cancer research.

[15]  M. Bally,et al.  Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes , 1997, Cancer Chemotherapy and Pharmacology.

[16]  M. Woodle,et al.  Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.

[17]  H. Jablonowski,et al.  Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. , 1996, British Journal of Cancer.

[18]  M. Bally,et al.  Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. , 1990, Cancer letters.

[19]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[20]  D. Lasič,et al.  Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes , 1992, International journal of cancer.

[21]  Y. Barenholz,et al.  In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. , 1992, Biochimica et biophysica acta.

[22]  F. Martin,et al.  Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. , 1993, Cancer research.

[23]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[24]  Y. Hashimoto,et al.  Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. , 1997, British Journal of Cancer.

[25]  P. Gullino,et al.  Bulk transfer of fluid in the interstitial compartment of mammary tumors. , 1975, Cancer research.

[26]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[27]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[28]  K. Maruyama,et al.  Immunoliposomes bearing polyethyleneglycol‐coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo , 1997, FEBS letters.

[29]  S. Watanabe,et al.  Endocytosis does not necessarily augment the cytotoxicity of adriamycin encapsulated in immunoliposomes. , 1994, Biochimica et biophysica acta.

[30]  J. Roh,et al.  Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. , 1986, Cancer research.

[31]  H. Harashima,et al.  Effects of the size and fluidity of liposomes on their accumulation in tumors: A presumption of their interaction with tumors , 1995 .

[32]  J. Kahn,et al.  Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. , 1993, Journal of acquired immune deficiency syndromes.

[33]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[34]  A. C. Begg,et al.  Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. , 1988, British Journal of Cancer.

[35]  H. H. Lloyd,et al.  Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. , 1970, Cancer chemotherapy reports.

[36]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[37]  H. Harashima,et al.  Kinetic study on the optimization of tumor delivery of antitumor agents by liposomes: Simulation study based on the physiological modeling. , 1997 .

[38]  E. Mayhew,et al.  Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes , 1993, Cancer.

[39]  M. Namer,et al.  Doxorubicin weekly low dose administration: in vitro cytotoxicity generated by the typical pharmacokinetic profile. , 1992, European journal of cancer.

[40]  F. Martin,et al.  Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.

[41]  B. Tromberg,et al.  Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. , 1996, Cancer research.

[42]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[43]  R. Johnson,et al.  Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia. , 1978, Biochemical pharmacology.

[44]  N. Oku,et al.  Long-circulating liposomes. , 1994, Critical reviews in therapeutic drug carrier systems.

[45]  D. Crommelin,et al.  Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat. , 1984, Cancer research.

[46]  H. Harashima,et al.  Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II) , 1992, Biopharmaceutics & drug disposition.

[47]  D Needham,et al.  Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.

[48]  Y. Sugiyama,et al.  Evaluation of the efficiency of targeting of antitumor drugs: simulation analysis based on pharmacokinetic/pharmacodynamic considerations. , 1996, Journal of drug targeting.

[49]  A. Gabizon.  Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.

[50]  M. Shimoyama,et al.  Quantitative clonal growth of mammalian cells: its application for quantitative study of cytocidal action of Mitomycin-C. , 1972, Gan.

[51]  M. Relling,et al.  Clinical Pharmacokinetics-Pharmacodynamics of Anticancer Drugs , 1989, Clinical pharmacokinetics.

[52]  S. Bielack,et al.  Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. , 1989, European journal of cancer & clinical oncology.

[53]  R. Jain,et al.  Residence time distributions of various tracers in tumors: implications for drug delivery and blood flow measurement. , 1994, Journal of the National Cancer Institute.

[54]  S. Arbuck,et al.  Free and liposomal doxorubicin treatment of intraperitoneal colon 26 tumor: therapeutic and pharmacologic studies. , 1990, Selective cancer therapeutics.

[55]  F M Muggia,et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  T M Allen,et al.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.

[57]  K Yamaoka,et al.  A nonlinear least squares program based on differential equations, MULTI (RUNGE), for microcomputers. , 1983, Journal of pharmacobio-dynamics.